Clinical Trials

  • Principal Investigator:

    Cynthia Gyamfi-Bannerman, MD
    This research study is being done to is to understand how CPAP for sleep apnea may affect hypertensive disorders of pregnancy and other complications of pregnancy such as gestational diabetes. The purpose of the home sleep test is to find women with sleep apnea. Sleep apnea is when you have one or more pauses in breathing or shallow breaths while you sleep. Studies have shown that women with sleep apnea have an increased risk of high blood pressure and diabetes during pregnancy. If the test shows that you have sleep apnea in the mild to moderate range you will be eligible for a research study...
  • Principal Investigator:

    Paula M. Castano, MD, MPH
    Nexplanon a contraceptive implant is currently approved for use up to 3 years. This study is looking to evaluate the contraceptive efficacy of Nexplanon during extended use for 2 more years (5 years total). You may be eligible if you are between the ages of 18-35 and are approaching 36 months from placement of your Nexplanon implant. Study participation would last 3 years and would require the completion of 11 study visits. Compensation for time and travel will be available upon completion of each study visit.
  • Principal Investigator:

    Paula M. Castano, MD, MPH
    Nexplanon a contraceptive implant is currently approved for use up to 3 years. This study is looking to evaluate the contraceptive efficacy of Nexplanon during extended use for 2 more years (5 years total). You may be eligible if you are between the ages of 18-35 and are approaching 36 months from placement of your Nexplanon implant. Study participation would last 3 years and would require the completion of 11 study visits. Compensation for time and travel will be available upon completion of each study visit.
  • Principal Investigator:

    Jason D. Wright, MD
    The purpose of this study is to find out if the study drug, HE4 has the potential to improve performance of biomarker CA 125 to determine recurrence of epithelial ovarian cancer before detecting the cancer clinically, surgically or through radiological scans. HE4 (Human Epididymis Protein 4) is a biomarker expressed in the normal lining of the female genital tract and breast. CA 125 is a protein found on the surface of ovarian cancer cells. Study visits will consist of 5 minute blood draws.
  • Principal Investigator:

    Carolyn L. Westhoff, MD
    Did you have unprotected sex? Do you weigh at least 176 pounds? This clinical trial is an experimental research study using a new dose of emergency contraception or morning-after pill. You may qualify if you: Are a premenopausal, healthy woman between the ages of 18 and 40. Weigh more than 176 pounds. Have an intact uterus with at least one ovary. Have regular menstrual cycles. If you qualify, you will: Receive a free investigational emergency contraceptive pill. Comply with protocol requirements, including taking an oral medication. Attend approximately 2 clinic visits and receive follow up...
  • Principal Investigator:

    Carolyn L. Westhoff, MD
    Did you have unprotected sex? Do you weigh at least 176 pounds? This clinical trial is an experimental research study using a new dose of emergency contraception or morning-after pill. You may qualify if you: Are a premenopausal, healthy woman between the ages of 18 and 40. Weigh more than 176 pounds. Have an intact uterus with at least one ovary. Have regular menstrual cycles. If you qualify, you will: Receive a free investigational emergency contraceptive pill. Comply with protocol requirements, including taking an oral medication. Attend approximately 2 clinic visits and receive follow up...
  • Principal Investigator:

    June Y. Hou, MD
    The purpose of the first part of this study, the Dose Escalation part, is to study and identify the highest tolerable safe dose of MORAb-202. The purpose of the Expansion part is to further investigate how the different tumor types being studied respond to the study drug and to gather more information on its safety and effectiveness. This study will enroll patients with triple-negative breast cancer (TNBC), endometrial cancer (EC), non-small cell lung cancer (NSCLC, adenocarcinoma), primary peritoneal cancer or fallopian tube cancer, and ovarian cancer. If it is determined that you meet all...
  • Principal Investigator:

    Carolyn L. Westhoff, MD
    If you are a woman between the ages of 18 and 35, are pre-menopausal, sexually active and do NOT wish to become pregnant, you are invited to see if you may qualify for a research study. The purpose of this research study is to test the effectiveness of an investigational oral birth control pill. If you qualify, you will receive investigational study medication, study-related medical exams, and laboratory services at no charge. You may also be reimbursed for time, travel, and other expenses.
  • Principal Investigator:

    Jason D. Wright, MD
    HE4 (Human Epididymis Protein 4) is a biomarker expressed in the normal lining of the female genital tract and breast. We are doing this research study to if HE4 is an indicator of treatment response during initial therapy for Primary Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancers. For this we will collect blood at specific intervals. You are being asked to take part in this study because you have been diagnosed with Primary Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer and will be receiving initial treatment for your disease.
  • Principal Investigator:

    Ana Isabel Tergas, MD
    AstraZeneca AB (AstraZeneca) is doing this research to find out if durvalumab, when given with chemoradiotherapy will help to treat cervical cancer.

Pages